Mark Velleca

Black Diamond Therapeutics is a medical company focused on analyzing genetically defined cancers.

Raised $272,100,000.00 from Nextech Invest, Biotechnology Value Fund, Logos Capital, Perceptive Advisors, Invus, Wellington Management, Versant Ventures, New Enterprise Associates, Roche Venture Fund and City Hill Ventures.

Myeloid Therapeutics is a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases.

Raised $189,320,327.00 from 8VC, ARCH Venture Partners, Alexandria Venture Investments, Moore Strategic Ventures, Newpath Management, Hatteras Venture Partners, Hatteras Venture Partners, Alexandria Venture Investments and 8VC.

G1 Therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology.

Raised $697,368,007.00 from Hercules Capital.

Venture Capital Multiplier Fund is a venture capital firm

StrideBio is a gene therapy company that develops genetic medicines with curative potential for patients with devastating conditions.

Raised $97,200,000.00 from Northpond Ventures, CaaS Capital Management, Takeda Ventures, Sarepta Therapeutics, Alexandria Venture Investments, Novo Holdings, UCB Ventures, UF Innovate Ventures, Pontifax and Octagon Capital Advisors.

G1 Therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology.

Raised $697,368,007.00 from Hercules Capital.

Gilead Sciences is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases.

Raised $4,413,500,000.00 from Abingworth.